Catalyst Capital Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Catalyst Capital Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-255	Closed	-$7K	–	591
2018 Q1	$7K	Hold	255	–	–	﹤0.01%	373
2017 Q4	$7K	Hold	255	–	–	﹤0.01%	369
2017 Q3	$6K	Hold	255	–	–	﹤0.01%	396
2017 Q2	$6K	Buy	+255	New	+$5.37K	﹤0.01%	442

Other funds holding DOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Catalyst Capital Advisors's DOVA Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2018, closing a stake of 255 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in DOVA in Q2 2017 and held it in 4 quarters. The position peaked at $7K in Q1 2018. 60 funds tracked by Wall St. Rank hold DOVA as of Q2 2018.

Catalyst Capital Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 255 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $7K.
Catalyst Capital Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Catalyst Capital Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $7K in Q1 2018.
60 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.